Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vomiting 2Uterine Cervical Neoplasms 1Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy 1Neoplasms 1Nausea 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Gynecologic Cancer 1Genital Neoplasms, Female 1

Interventions

fosaprepitant 1Prochlorperazine 1Preoperative Exercise 1Ondansetron 1Olanzapine 1Neurokinin-1 Receptor Antagonists 1FloSeal Matrix 1Ferric Oxide, Saccharated 1Enhanced Recovery After Surgery 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Gynecologic Cancer × fosaprepitant × Clear all
NCT04503668 2025-06-18

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

University of Michigan Rogel Cancer Center

Phase 3 Terminated
62 enrolled 16 charts
Gynecologic

Gynecologic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡